KULA, Maui, Hawaii, May 03, 2007 /PRNewswire-FirstCall/ --
Bioponic Phytoceuticals, Inc. ("Bioponic" or "the Company") today announced that its Curecumin(TM) (a Bioresonant Phytotherapeutic(R) form of curcumin in a liquid delivery system) may be an important treatment for Skin Cancer.
In a recent study published in the Journal of Biological Chemistry, "Curcumin Suppresses AP1 Transcription Factor-dependent Differentiation and Activates Apoptosis in Human Epidermal Keratinocytes," conducted at the Departments of Physiology and Biophysics, Dermatology, Biochemistry, Reproductive Biology, and Oncology, at School of Medicine in Cleveland, Ohio. Scientists concluded, "The diet-derived cancer preventive agent, curcumin, inhibits skin cancer cell proliferation and tumor formation ... We show that curcumin suppresses the differentiation agent-dependent activation of hINV gene expression and that an AP1 transcription factor DNA binding site in the hINV gene is required for this regulation ... These studies provide important insights regarding the mechanism whereby curcumin acts as a chemopreventive agent in normal human epidermis."